Genetic variability in the major capsid L1 protein of human papillomavirus type 16 (HPV-16) and 18 (HPV-18)

Infection, Genetics and Evolution

Volumn 11, Issue 8, 2011, Pages 2119-2124

  Frati, E ^a   Bianchi, S ^a   Colzani, D ^a   Zappa, A ^a   Orlando, G ^b   Tanzi, E ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Cervical cancer; HPV 16; HPV 18; Immunodominant epitopes; Intratypic variants; L1 capsid protein

Indexed keywords

CAPSID PROTEIN L1;

ARTICLE; BIOLOGICAL ACTIVITY; CODON; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENETIC POLYMORPHISM; GENETIC SELECTION; GENETIC VARIABILITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; L1 GENE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; VIRUS GENE; VIRUS MUTATION; VIRUS TYPING;

CAPSID PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENE PROTEINS, VIRAL; PHYLOGENY; POLYMORPHISM, GENETIC; SELECTION, GENETIC; SEQUENCE ALIGNMENT; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE;

EID: 82655172506     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2011.06.014     Document Type: Article

References (39)

1. Alvarez-Salas L.M., DiPaolo J.A. Molecular approaches to cervical cancer therapy. Curr. Drug. Discov. Technol. 2007, 4:208-219.
2. Bernard H.U. Gene expression of genital human papillomaviruses and considerations on potential antiviral approaches. Antivir. Ther. 2002, 7:219-237.
3. Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., zur Hausen H., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
4. Bishop B., Dasgupta J., Klein M., Garcea R.L., Christensen N.D., Zhao R., Chen X.S. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J. Biol. Chem. 2007, 282:31803-31811.
5. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 2002, 55:244-265.
6. Carter J.J., Wipf G.C., Madeleine M.M., Schwartz S.M., Koutsky L.A., Galloway D.A. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J. Virol. 2006, 80:4664-4672.
7. Chen Z., DeSalle R., Schiffman M., Herrero R., Burk R.D. Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97. J. Virol. 2009, 83:1443-1455.
8. Chen Z., Terai M., Fu L., Herrero R., DeSalle R., Burk R.D. Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J. Virol. 2005, 79:7014-7023.
9. Chen X.S., Garcea R.L., Goldberg I., Casini G., Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell. 2000, 5:557-567.
10. Christensen N.D., Cladel N.M., Reed C.A., Budgeon L.R., Embers M.E., Skulsky D.M., McClements W.L., Ludmerer S.W., Jansen K.U. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 2001, 291:324-334.
11. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., Cladel N.M., Galloway D.A. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996, 223:174-184.
12. Christensen N.D., Kreider J.W. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J. Virol. 1990, 64:3151-3156.
13. Danos O., Katinka M., Yaniv M. Human papillomavirus 1a complete DNA sequence. a novel type of genome organization among papovaviridae. Embo J. 1982, 1:231-236.
14. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324:17-27.
15. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985, 39:783-791.
16. Gagnon S., Hankins C., Money D., Pourreaux K., Franco E., Coutlee F. Polymorphism of the L1 capsid gene and persistence of human papillomavirus type 52 infection in women at high risk or infected by HIV. J. Acquir. Immune Defic. Syndr. 2007, 44:61-65.
17. Hildesheim A., Schiffman M., Bromley C., Wacholder S., Herrero R., Rodriguez A., Bratti M.C., Sherman M.E., Scarpidis U., Lin Q.Q., Terai M., Bromley R.L., Buetow K., Apple R.J., Burk R.D. Human papillomavirus type 16 variants and risk of cervical cancer. J. Natl. Cancer Inst. 2001, 93:315-318.
18. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 1998, 338:423-428.
19. Icenogle J.P., Clancy K.A., Lin S.Y. Sequence variation in the capsid protein genes of human papillomavirus type 16 and type 31. Virology 1995, 214:664-669.
20. Jukes T.H., Cantor C.R. Evolution of protein molecules. Mammalian Protein Metabolism 1969, 21-132. Academic Press, New York. H.N. Munro (Ed.).
21. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 1980, 16:111-120.
22. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 1992, 89:12180-12184.
23. Li N., Franceschi S., Howell-Jones R., Snijders P.J.F., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer 2011, 128:927-935.
24. Moscicki A.B., Smith J.S. Issues in human papillomavirus vaccination in adolescents. J. Adolesc. Health 2008, 43:S1-4.
25. Nei M., Gojobori T. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol. Biol. Evol. 1986, 3:418-426.
26. Olcese V.A., Chen Y., Schlegel R., Yuan H. Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. BMC Microbiol. 2004, 4:29.
27. Ong C.K., Chan S.Y., Campo M.S., Fujinaga K., Mavromara-Nazos P., Labropoulou V., Pfister H., Tay S.K., ter Meulen J., Villa L.L., et al. Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J. Virol. 1993, 67:6424-6431.
28. Pastrana D.V., Vass W.C., Lowy D.R., Schiller J.T. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 2001, 279:361-369.
29. Pista A., Oliveira A., Barateiro A., Costa H., Verdasca N., Paixao M.T. Molecular variants of human papillomavirus type 16 and 18 and risk for cervical neoplasia in Portugal. J. Med. Virol. 2007, 79:1889-1897.
30. Raiol T., Wyant P.S., de Amorim R.M., Cerqueira D.M., Milanezi N.G., Brigido Mde M., Sichero L., Martins C.R. Genetic variability and phylogeny of the high-risk HPV-31, -33, -35, -52, and -58 in central Brazil. J. Med. Virol. 2009, 81:685-692.
31. Roden R.B., Armstrong A., Haderer P., Christensen N.D., Hubbert N.L., Lowy D.R., Schiller J.T., Kirnbauer R. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J. Virol. 1997, 71:6247-6252.
32. Saitou N., Nei M. The Neighbor-Joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 1987, 4:406-425.
33. Stewart A.C., Eriksson A.M., Manos M.M., Munoz N., Bosch F.X., Peto J., Wheeler C.M. Intratype variation in 12 human papillomavirus types: a worldwide perspective. J. Virol. 1996, 70:3127-3136.
34. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 2007, 24:1596-1599.
35. Varsani A., Williamson A.L., Jaffer M.A., Rybicki E.P. A deletion and point mutation study of the human papillomavirus type 16 major capsid gene. Virus Res. 2006, 122:154-163.
36. Wheeler C.M., Yamada T., Hildesheim A., Jenison S.A. Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. J. Clin. Microbiol. 1997, 35:11-19.
37. White W.I., Wilson S.D., Bonnez W., Rose R.C., Koenig S., Suzich J.A. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J. Virol. 1998, 72:959-964.
38. Yamada T., Manos M.M., Peto J., Greer C.E., Munoz N., Bosch F.X., Wheeler C.M. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J. Virol. 1997, 71:2463-2472.
39. Yamada T., Wheeler C.M., Halpern A.L., Stewart A.C., Hildesheim A., Jenison S.A. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J. Virol. 1995, 69:7743-7753.